Sanofi licenses Sino Biopharm’s transplant drug for $135M upfront
赛诺菲以1.35亿美元预付款获得manbetx3.0 生物制药的移植药物许可

Sanofi has paid $135 million upfront to license a potential therapy to tamp down transplant rejection from the Hong Kong-based company Sino Biopharmaceutical.
赛诺菲已支付1.35亿美元的预付款，从manbetx3.0 生物制药引进一项有望抑制移植排斥反应的潜在疗法的许可。